58 results about "Squamous cancer" patented technology

Methods and device for detecting the presence of tumor biomarkers in oral squamous cell carcinoma. A membrane based cell capture device allows deliver of cell samples and reagents to the membrane

The invention provides a four-autoantibody combined detection kit for diagnosing an early esophageal squamous cancer and application thereof. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer comprises a solid substrate and antigen protein which coats the solid substrate; and the antigen protein comprises TP53, HRAS, CTAG1A and NSG1. The four-autoantibody combined detection kit for diagnosing the early esophageal squamous cancer, provided by the invention, has the advantages that the TP53, the HRAS, the CTAG1A and the NSG1 are firstly adopted as acombination to be used for early diagnosis of ESCC, higher sensibility and higher specificity are realized, the detection kit is conducive to further improvement of serologic screening quality of ESCC early diagnosis, and therefore, the cure rate and survival rate of patients are further promoted.

The invention discloses a gene expression classifier for predicting colonic adenocarcinoma prognosis, and an establishment method for the classifier. The establishment method comprises a data training stage and a verification stage. The training stage comprises a first stage and a second stage; in the first stage, a gene expression classifier prototype capable of predicting the colonic adenocarcinoma prognosis is established by using a supervised machine learning method; and in the second stage, the gene expression classifier for predicting the colonic adenocarcinoma prognosis is obtained by further using the machine learning method. The gene expression classifier can predict not only prognosis of patients suffering from colonic adenocarcinoma but also prognosis of patients suffering from kidney cancers, lung squamous cancers, eye ground and skin melanin tumors, brain cancers and pancreatic cancers, thereby providing accurate judgment criteria for postoperative adjuvant treatment of the patients suffering from the cancers.

The invention discloses a 3D model constructed in vitro by means of a serum-free culture medium as well as a construction method of the 3D model and relates to the technical field of biological materials in tissue engineering. Due to selection variety of seed cells and good in-vitro construction repeatability, industrial preparation of the 3D model can be realized. The model is an in-vitro model formed by primary corneal epithelial cells subjected to tissue isolation, limbal stem cells, immortalized corneal epithelial cells, primary oral epithelial cells or oral mucosa squamous cancer cell lines TR146 subjected to in-vitro amplification and stratified through the serum-free culture medium with an undersurface-gas-liquid surface staged culture method.

The invention discloses applications of miR-455-3p in the diagnosis, treatment, and prognosis of esophageal squamous cancer. The inventor finds that the obviously low survival rate of ESCC patients is related with the high expression of miR-455-3p in ESCC patients. The in-vitro and in-vivo experiment results show that miR-455-3p is capable of promoting the malignant progression of ESCC, by inhibiting the expression of miR-455-3p, the ESCC stem cell characteristics can be inhibited, and the sensitivity of ESCC stem cells to chemotherapy drugs is enhanced; so an expression inhibitor of miR-455-3p can inhibit the tumor stem cells, and is capable of inhibiting the tumor stem cell characteristics and enhancing the sensitivity of the cancer stem cells to chemotherapy drugs. The invention finds the expression of miR-455-3p in cancer patients for the first time, and the expression can be used as auxiliary diagnosis and / or prognosis of ESCC. The invention provides a novel diagnosis method, a novel treatment method, and a pharmaceutical drug screening platform for tumor diseases.

The invention provides an oral mucosa epithelium model and an in-vitro construction method thereof and belongs to the technical field of tissue engineering biological materials. The in-vitro oral mucosa epithelium model is formed through stratification of one or two of oral mucosa squamous cancer cell lines TR146, Tca8113, SCC-4, SCC-9, SCC-25,HN-6 and CAL-27 with an air-liquid interface culture method adopting different culture systems at different stages after in-vitro amplification according to cytobiology and engineering principles.

The invention provides an establishing method of a Chinese tongue squamous cancer cell line (CTSC-1), and provides a material base for researching the characteristics of tongue squamous cancer and therapeutics thereof. The establishing method comprises the steps of: carrying out primary culture on the tongue squamous cancer cells by adopting a tissue explants adherent method; subculturing when the cell density reaches about 80 percent; carrying out RT-PCR (Reverse Transcription-Polymerase Chain Reaction) detection on stably subcultured cells to indicate that the cells express tongue squamous cancer cell symbolic molecules CK 8, 18 and 19; and detecting adherent cells through a western blot test to express proteins of the tongue squamous cancer cell symbolic molecules CK 8 and 18, therefore, proving on a molecular level the successful establishment of the CTSC-1.

The invention belongs to the technical field of medicines and relates to a benzothiazole formamide compound and application thereof. The benzothiazole formamide compound comprises a derivative of the benzothiazole formamide compound and pharmaceutically applicable salt; a general molecular formula is shown in the description, wherein R1, R2 and Ar are described as claims and the description. The benzothiazole formamide compound and addition salt of the pharmaceutically applicable acid of the compound can be combined with an existing medicine or can be independently utilized as an epidermal growth factor tyrosine kinase inhibitor for treating related diseases of epidermal growth factor acceptor signal transduction disorder, such as small cell lung cancer, squamous cancer, glandular cancer, large cell lung cancer, colorectal cancer, breast cancer, ovarian cancer and renal cell carcinoma. A formula is shown in the description.

The invention relates to an antitumor application of penicillium enol A2 from penicillium citrinum. Penicillium citrinum IBPT-5 is preserved at the China Center for Type Culture Collection on December 25, 2013; the address is Wuhan University; and the preservation number is CCTCC NO:M 2013713. An experiment proves that the compound has relatively good antitumor activity on a plurality of tumor cells, and can be used for preparing cell proliferation inhibition drugs or antitumor drugs to carry out antitumor research; and the tumor cells comprise human colon cancer cells SW620, human hepatoma carcinoma cells Huh7, human colon cancer cells SW480, human esophageal squamous cancer cells KYSE450, human esophageal carcinoma cells EC9706 and human hepatoma cells PLC.

Methods of detecting lung cancer, such as non-small cell lung cancer, including squamous cell carcinoma and adenocarcinoma, are provided. Methods of detecting changes in the levels of one or more small RNAs associated with lung cancer are also provided. Compositions and kits are also provided.

The invention relates to the use of a microRNA-548k inhibitor in treatment and / or prevention of the esophageal squamous cancer. Further the invention relates to the microRNA-548k as a molecule marker used for diagnosing the esophageal squamous cancer.

The invention provides an immune-enhancing antineoplastic collagen composition as well as a preparation method and an application thereof. The composition is characterized by consisting of antineoplastic factors, collagen, polysaccharide substances and active factors. The composition is applicable to, but not limited in, cells for treating breast cancer, colorectal cancer, ovarian cancer, pancreatic cancer, prostatic cancer, bladder cancer, melanoma, lung cancer, stomach cancer, liver cancer, head and neck squamous cell carcinoma, carcinoma of uterine cervix, renal cell carcinoma, thyroid cancer, acute myeloid leukemia, myeloma, esophageal squamous cancer, lymphoma and the like.

The invention discloses a use of a bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors. Anti-cancer experiments of human tongue squamous cancer cells are carried out in vitro through a bufadienolide extract and monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, cinobufagin, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, and experimental results show that the bufadienolide compound has strong inhibition effect on tongue squamous cancer cells and compared with the bufadienolide extract and eight monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, cinobufagin has a stronger anti-tumor cell activity. The bufadienolide compound provided by the invention has clear components, controllable quality, strong anti-tumor activity and little adverse reaction and is expected to be developed into a novel anti oral mucosal malignant tumor medicine.

The invention discloses an esophageal cancer cell line and application thereof. The esophageal cancer cell line is named as a human esophageal squamous cancer cell line ZEC-145 and collected under CCTCC NO: C201686. The human esophageal squamous cancer cell line ZEC-145 comes from tumor tissue of a Chinese patient with esophageal cancer after excision, STR detection results show that the human esophageal squamous cancer cell line ZEC-145 is unique, no cross contamination with other cells occurs in the process of primary culture, clone formation and tumorigenicity is high, and the esophageal cancer cell line can serve as an ideal cell line in the application aspects of esophageal cancer studying, esophageal cancer detection kit development and drug screening.

The invention belongs to the field of tea germplasm resources, and particularly relates to a breeding method of an improved variety of tea trees with a tumor inhibition function. The method comprises the following steps: carrying out geographical distant cross, measuring the content of biological active components in dry fresh tea tree leaves of a crossing offspring, and selecting germplasm with the basic active ingredient content of tea trees as the improved variety of tea trees with the tumor inhibition function, wherein the total content of catechin is more than or equal to 22 percent, the content of EGCG is more than or equal to 12 percent, the content of catechin C is more than or equal to 2 percent, the content of ECG is more than or equal to 3.5 percent, and the content of caffeine is more than or equal to 4.5 percent. Tealeaves produced by adopting the improved variety are tealeaves with the tumor inhibition function. The tealeaves can in vitro efficiently inhibit the growth of cells of 13 human tumors such as liver cancer, ovarian cancer, cervical cancer, lung cancer, brain star spongioblastoma, breast ductal cancer, prostatic cancer, leukaemia, gastric cancer, colon cancer, skin squamous cell carcinoma and pancreatic cancer and has effect for efficiently inhibiting the growth of human lung cancer cell transplantation tumor in an animal body.

The present invention relates to a pharmaceutical composition containing apigenin, an apigenin derivative, rubescensin, and a rubescensin derivative, and applications of the pharmaceutical composition for preparing pharmaceuticals to cure lung cancer, pancreas cancer, colorectal carcinoma, liver cancer, prostate cancer, kidney cancer, stomach cancer, brain tumor, sarcoma, mesothelioma, head and neck squamous cancer, ovary cancer or breast cancer. The pharmaceutical composition has an obvious synergistic effect, increases the pharmic curative effect, reduces the administration dosage and reduces the adverse reactions.

The invention discloses an isatin derivative synthesized by an isatin hybrid quinazoline compound and application thereof in preparing antineoplastic drugs. The structural formula of the derivative is shown in the description, wherein X represents hydrogen, fluorine, chlorine, bromine or iodine, Ar represents 3-acetenyl phenyl, 4-(E)-allyl phenyl, 3-Chloro-4-(3-fluorobenzyloxy)-phenyl or 3-chloro-4-fluorophenyl. The synthesis method of the isatin derivative is simple, and the isatin derivative synthesized by an isatin hybrid quinazoline compound has obvious inhibition effect on the proliferation of human skin squamous cancer cells A431, human lung cancer cells NCI-H1975, human colon cancer cells SW480 and human non-small cell lung cancer cells A549 and can be applied in preparing the antineoplastic drugs.

This invention encompasses an expeditious method and compositions that have been found to show selective cytotoxicity against several different cancer cell lines. for treating a wide variety cancer neoplasms that have tumor microenvironments by administering a stand-alone anti-tumor chemotherapeutic composition or administered as an adjunct with chemotherapy and / or radiotherapy with enhanced tumor site affinity that preferentially elevates the pH at the tumor site to suppress and eliminates the acidic tumor microenvironment, administered as chemosensitizing and / or radiosensitizers enhancing the tumor, suppression, remission and inhibit tumor metastisis. The invention encompasses controlling mechanisms of intracellular and extracellular ionic physiology through the administration of alkali salts for pH modulating and for restoring and enhancing ionic physiology. The compositions are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs), thereby inhibiting angiogenesis, reducing metastatic proliferation, supressing tumor generated induced acidotic pain.

The invention relates to the use of an FAM135B inhibitor in treatment and / or prevention of the esophageal squamous cancer. Further the invention relates to the use of the FAM135B genome mutation in diagnosis and / or prognosis of the esophageal squamous cancer.

DNA methylation profiles predictive of head and neck squamous cell carcinoma (HNSCC) patient prognosis, as well as therapeutic protein and adoptive cell compositions useful in the treatment of HNSCC.

The present invention relates to a pharmaceutical combination for use in the treatment of squamous cell carcinoma, comprising a CDK inhibitor selected from the compounds of formula (I);or a pharmaceutically acceptable salt thereof and one or more antineoplastic agents selected from sorafenib, lapatinib, erlotinib, cisplatin, 5-fluorouracil, docetaxel or cetuximab or a pharmaceutically acceptable salt thereof. The said pharmaceutical combination exhibits synergy when used in the treatment of squamous cell carcinoma of head and neck (SCCHN). The invention also relates to a pharmaceutical composition comprising the said combination and a method for the treatment of squamous cell carcinoma of head and neck (SCCHN), using a therapeutically effective amount of said combination.

The invention discloses an esophageal cancer cell line and application thereof. The esophageal cancer cell line is named a human esophageal squamous cancer cell line ZEC-014, and the preservation number is CCTCC (China Center for Type Culture Collection) NO: C201689. The human esophageal squamous cancer cell line ZEC-014 disclosed by the invention comes from tumor tissues after excision of an esophageal cancer patient in China, an STR (Specialized Technology Resources) detection result shows that the human esophageal squamous cancer cell line ZEC-014 is unique and is not in cross contamination with other cells during a primary culture process, the clone formation ability and the tumorigenicity are strong, and the human esophageal squamous cancer cell line ZEC-014 can be used as an ideal cell line for application in respects of esophageal cancer research, esophageal cancer detection kit development, drug screening and the like.

The present invention discloses an application of typhoid and paratyphoid salmonella in the anti-tumor aspect, which is invented to solve the problems of great side effects and poor effects of the prior art in the treatment of tumors. The present invention provides the application of the typhoid and paratyphoid salmonella in the rapid anti-tumor aspect. Wherein, the tumors are one or more of gastric cancer, lung cancer, liver cancer, tongue squamous cancer, breast cancer, colon cancer, leukemia, brain tumor and sarcoma. The invention makes use of the rapid combination of the typhoid and paratyphoid salmonella with the mononuclear cells after entering into the human body, the strong endotoxin and bacteremia are released and the temperature reaches highly around 40 DEG C to 42 DEG C, so as to affect and inhibit the growth and the life cycle of the tumor cells, furthermore, the large mononuclear cells-macrophages in the reticuloendothelial system are proliferated greatly, thus enhancing the ability of the macrophages in vivo to swallow the cancer cells, so the invention has very significant inhibiting and killing effects of a variety of tumors.

The invention provides a spirosolane glycoalkaloid(3beta,5alpha,22alpha,25R)-spirosolane-3-O-beta-D-glucopyranosyl-(1 to 2)-O-beta-D-glucopyranosyl-(1 to 4)-beta-D-galactopyranoside, and a preparation method and a use thereof. The spirosolane glycoalkaloid has an inhibition effect on human lung gland cancer cell A549, human maxicell lung cancer cell H460 and human lung squamous cancer cell SK-MES-1, the 50% inhibiting concentration of the A549 cell is 19.22 [mu]g / ml, the 50% inhibiting concentration of the H460 cell is 80.03 [mu]g / ml, and the 50% inhibiting concentration of the SK-MES-1 cell is 54.20 [mu]g / ml. The (3beta,5alpha,22alpha,25R)-spirosolane-3-O-beta-D-glucopyranosyl-(1 to 2)-O-beta-D-glucopyranosyl-(1 to 4)-beta-D-galactopyranoside prepared in the invention, and a preparation thereof, can be used for treating non-small cell lung cancers.

A construction method of a lentivirus capable of specifically inhibiting a DCUN1D1 gene comprises the following steps: S1, interfering target design and primer synthesis: S2, annealing primers to formdouble-stranded fragments with sticky ends: S3, synthesizing a sequence containing a restrictive endonuclease recognition sequence and a DCUN1D1 gene interference site by PCR reaction. S4, preparinga linearized expression vector; S5, connecting ane interference fragment of the DCUN1D1 with a double-digested pLKD-CMV-eGFP-U6-shRNA vector to form a recombinant plasmid: S6, carrying out competent cell transformation, culture, screening and sequencing verification on the recombinant plasmid, and selecting a correctly cloned recombinant bacterial solution; S7, extracting plasmids in the correctlycloned recombinant bacterial solution by using a plasmid extraction kit; S8, carrying out lentivirus production for specifically inhibiting DCUN1D1 gene expression by using a Swiss virus packaging system;S9, verifying the expression of the DCUN1D1 protein after the lentivirus produced in the previous step is infected with the lung squamous cancer cells by Western blot.

The invention discloses a molecular target of esophageal squamous carcinoma. The molecular target is AGXT2L1. The invention uses gene chip and QPCR experiments to prove the differential expression of AGXT2L1 in esophageal squamous carcinoma, and also utilizes esophageal squamous cancer cell line to prove that AGXT2L1 has important effect on proliferation and migration of esophageal squamous carcinoma cells. The research result of the invention provides the theoretical basis for clinical realization of precise treatment, and provides a new molecular target for diagnosis of esophageal squamous carcinoma and research and development of treatment products.

The invention discloses an esophageal cancer cell line and application thereof. The esophageal cancer cell line is named as a human esophageal squamous cancer cell line ZEC-056 and collected under CCTCC NO: C201691. The human esophageal squamous cancer cell line ZEC-056 comes from tumor tissue of a Chinese patient with esophageal cancer after excision, STR detection results show that the human esophageal squamous cancer cell line ZEC-056 is unique, no cross contamination with other cells occurs in the process of primary culture, clone formation and tumorigenicity is high, and the esophageal cancer cell line can serve as an ideal cell line in the application aspects of esophageal cancer studying, esophageal cancer detection kit development and drug screening.